Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports that multiple senior executives and non-executive directors increased their holdings in its equity through dividend reinvestment plans. On 9 April 2026, cash dividends were reinvested into Ordinary Shares and American Depositary Shares held in the Company’s Deferred Annual Bonus Plan, a pension plan, or directly.
On 14 April 2026, CEO Luke Miels received a notional increase of 1,178 Ordinary Shares at £21.6700, and CFO Julie Brown received 1,553 Ordinary Shares at £21.6700. Other executives, including the Chief People Officer, Chief Digital and Technology Officer, and President, Corporate Development, received smaller Ordinary Share or ADS allocations at similar prices.
Several independent non-executive directors, such as Charles Bancroft and Dr Hal Barron, acquired modest amounts of ADS (for example 313 ADS at $58.9307) via dividend reinvestment on the New York Stock Exchange. These are plan-based acquisitions rather than open-market trading decisions.
GSK plc reports that on 15 April 2026 it repurchased 325,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,142.00p and 2,201.00p with a volume-weighted average price of 2,179.65p per share and will be held as Treasury shares.
The purchases were made under a non-discretionary agreement with the broker announced on 17 February 2026, since when GSK has repurchased 19,196,521 ordinary shares. After this transaction, GSK holds 259,087,615 shares in treasury and has 4,057,103,154 ordinary shares in issue, which is also the total number of voting rights.
GSK confirms that, in line with DTR 5.5.1R, the voting rights attributable to the ordinary shares held in treasury represent 6.39%. Detailed schedules list the quantities and prices executed across trading venues BATE, CHIX and XLON as part of the buyback activity.
GSK plc has completed its acquisition of 35Pharma Inc., a private, Canada-based clinical-stage biopharma company, for $950 million. The deal brings HS235, a potential best-in-class therapy targeting the activin receptor signalling pathway for pulmonary hypertension (PH), into GSK’s respiratory, immunology and inflammation pipeline.
HS235 is designed with enhanced selectivity intended to reduce bleeding and other adverse events seen with current pulmonary arterial hypertension treatments, and early studies have suggested possible metabolic benefits such as fat-selective weight loss and improved insulin sensitivity. GSK highlights that PH affects about 82 million people worldwide with limited treatment options and around 50% five-year survival, and plans to start proof-of-concept trials in pulmonary arterial hypertension and PH due to heart failure with preserved ejection fraction imminently.
GSK plc reports that, acting through BNP Paribas, it repurchased 325,000 ordinary shares on 14 April 2026 under its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,164.00p and 2,194.00p, with a volume‑weighted average price of 2,176.46p per share.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought back a total of 18,871,521 ordinary shares. After this transaction, the company holds 258,762,615 ordinary shares in treasury and has 4,057,428,154 ordinary shares in issue, which is also the total number of voting rights.
GSK notes that, in line with DTR 5.5.1R, 6.38% of its voting rights are now represented by ordinary shares held in treasury. The filing also provides detailed trade-by-trade disclosure across London Stock Exchange and CBOE Europe venues as part of the programme.
GSK plc reports that, acting through BNP Paribas, it repurchased 325,000 ordinary shares of 31¼ pence each on 13 April 2026 at prices between 2,154.00p and 2,180.00p, with a volume‑weighted average price of 2,169.64p.
The shares will be held as Treasury shares as part of GSK’s existing share buyback programme under a non‑discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has repurchased 18,546,521 ordinary shares.
After this transaction, GSK holds 258,437,615 ordinary shares in treasury and has 4,057,753,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.37% of the company’s voting rights.
GSK plc reported that several senior executives and persons closely associated with them acquired small amounts of GSK ordinary shares through dividend reinvestment. The transactions reflect dividends paid on 9 April 2026 being automatically used to buy additional shares in investment accounts.
On the London Stock Exchange, shares were acquired at prices around £21.50–£21.70 per share on 9 and 10 April 2026. Participants included CEO Luke Miels, who acquired 2,393.328 shares at £21.5039, and multiple presidents and senior officers, each completing a single, routine purchase.
GSK plc reported encouraging early-stage results for mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody-drug conjugate, in difficult-to-treat gynaecological cancers. In the phase 1 BEHOLD-1 trial, Mo-Rez monotherapy achieved confirmed objective response rates of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer at the highest doses tested.
The safety profile was described as manageable: very few patients stopped treatment because of treatment-related side effects, and serious side effects were mainly blood-related, which is typical for this drug class. Interstitial lung disease or pneumonitis occurred in 3% of patients and was mild to moderate. The median duration of response had not yet been reached at this interim analysis, suggesting responses may be durable but follow-up is ongoing.
On the back of these data, GSK plans to advance Mo-Rez into five pivotal global phase III trials in 2026 across ovarian and endometrial cancer settings, including earlier-line and maintenance use. This programme underscores GSK’s broader oncology strategy focused on antibody-drug conjugates and women’s cancers.
GSK plc reports that on 10 April 2026 it repurchased 325,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,157.00p and 2,196.00p, with a volume-weighted average price of 2,182.28p, and will be held as treasury shares.
Since 17 February 2026, GSK has bought 18,221,521 ordinary shares. Following this latest transaction, it holds 258,112,615 shares in treasury and has 4,058,078,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.36% of voting rights, a figure shareholders can use when assessing notification thresholds.
GSK plc reports routine insider share acquisitions linked to its Share Reward Plan. Several senior executives and persons closely associated with them acquired small numbers of GSK ordinary shares of 31¼ pence each through the automatic reinvestment of dividends paid on 9 April 2026.
Transactions were executed on the London Stock Exchange at prices of £21.3387 and £21.5039 per share, with individual amounts ranging from low single-digit shares to just over 1,000 shares. These acquisitions reflect dividend reinvestment rather than open-market buying decisions.
GSK plc reports that on 09 April 2026 it repurchased 330,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing buyback programme. The volume-weighted average price was 2,139.38p, with prices between 2,124.00p and 2,158.00p per share.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 17,896,521 ordinary shares. After this transaction, it holds 257,787,615 ordinary shares in treasury and has 4,058,396,834 ordinary shares in issue, all carrying voting rights.
GSK states that the total number of voting rights is 4,058,396,834 and confirms that, following this purchase, ordinary shares held in treasury represent 6.35% of its voting rights.